Clinical trials: SC Disease
Sickle Cell Disease, Venous Thromboembolism
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation.
- Trial name
- DrepAgreg (NCT07852442)
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Sickle Cell Disease
Screening Patients With Sickle Cell Disease for Kidney Damage
This study aims to study the temporal course of sickle nephropathy and assess novel biomarkers that can predict patients prone to nephropathy.
- Trial name
- NCT02239016
- Where
- 4 sites in United States
- Volunteers
- 320 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Posttraumatic Stress Disorder (PTSD), Intrinsic and Novelty-related Sensory Cortical (SC) Disinhibition
A Neurosensory Account of Anxiety and Stress (Study 1)
This study will take a basic neuroscience approach to investigate pathological mechanisms underlying PTSD. Additionally, the study aims to identify how Transcranial Alternating Current Stimulation (tACS) brain stimulation can…
- Trial name
- NCT05895006
- Testing
- Alternating Current Stimulation (tACS), Transcranial Random Noise stimulation (tRNS)
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Primary Immune Thrombocytopenia
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune…
- Trial name
- NCT06594146
- Testing
- CM313 injection
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Keymed Biosciences Co.Ltd
Ulcerative Colitis, Crohn's Disease
Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
The purpose of this study is to assess the bioavailability and pharmacokinetics (PK) of multiple doses of vedolizumab subcutaneous (SC) compared to vedolizumab intravenous (IV).
- Trial name
- NCT02913508
- Testing
- Vedolizumab intravenous injection, Vedolizumab subcutaneous injection
- Sponsor
- Takeda
Systemic Lupus Erythematosus
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
The purpose of this study is to assess the PK, PD, and safety of anifrolumab as SC administration or IV infusion in adult participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT07688980
- Testing
- Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS
- Volunteers
- 92 people
- Sponsor
- AstraZeneca
Posttransplant Lymphoproliferative Disorder
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Post-transplant lymphoproliferative disorders (PTLD) differ clinically from lymphoma in the general (immunocompetent) population due to their higher incidence and their frequent association with Epstein-Barr virus.
- Trial name
- PTLD-2 (NCT02042391)
- Testing
- Rituximab sc, Rituximab sc consolidation, Rituximab sc combined with CHOP chemotherapy
- Where
- 18 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH
Muscular Dystrophies
A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration
The purpose of the extension phase of this study is to determine whether Drisapersen is effective in the treatment of boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.
- Trial name
- NCT01910649
- Testing
- Drisapersen
- Volunteers
- 12 people
- Sponsor
- BioMarin Pharmaceutical
Multiple Sclerosis
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary…
- Trial name
- PORTAMENTO (NCT07074886)
- Testing
- Ocrelizumab Test Formulation, Ocrelizumab Reference Formulation
- Where
- 49 sites in United States, Argentina and 7 more
- Volunteers
- 193 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).
- Trial name
- BeyoND (NCT02726386)
- Testing
- ND0612
- Where
- 57 sites in United States, Austria and 7 more
- Volunteers
- 214 people
- Sponsor
- NeuroDerm Ltd.
Asthma
Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma
Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with persistent asthma.
- Trial name
- NCT00425061
- Testing
- IMA-638
- Where
- 82 sites in United States, Canada
- Volunteers
- 159 people
- Sponsor
- Pfizer
Sickle Cell Disease, Sickle-Cell; Hemoglobin Disease, Thalassemia
Pharmacokinetics of Oral Hydroxyurea Solution
An open label, safety and pharmacokinetic study of oral hydroxyurea solution administered to children from 6 months to 17.99 years (i.e.
- Conditions
- Sickle Cell Disease, Sickle-Cell; Hemoglobin Disease, Thalassemia, Sickle Cell-beta-thalassemia, Sickle Cell Hemoglobin C
- Trial name
- HUPK (NCT03763656)
- Testing
- Oral Hydroxyurea (100 mg/mL) Solution
- Where
- 6 sites in Jamaica, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Nova Laboratories Limited
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This was a prospective, multicenter, open label extension (OLE) trial on the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK and PD of efgartigimod PH20 SC in adult PV or PF participants, who…
- Trial name
- ADDRESS+ (NCT04598477)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 127 sites in United States, Australia and 19 more
- Volunteers
- 183 people
- Sponsor
- argenx
Rheumatoid Arthritis
Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday
RA (rheumatoid arthritis) patients effectively treated weekly with SC (subcutaneous) Abatacept will be switched to IV (intravenous) Abatacept and restarted with SC Abatacept four after IV application.
- Trial name
- A-BREAK (NCT01846975)
- Testing
- IV Abatacept
- Where
- Switzerland
- Volunteers
- 49 people
- Sponsor
- Rüdiger B. Müller
Osteoporosis, Osteopenia
Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass
This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.
- Trial name
- NCT01604057
- Testing
- ZT-034 Low Dose Nasal Spray, ZT-034 Mid Dose Nasal Spray, ZT-034 High Dose Nasal Spray
- Volunteers
- 130 people
- Sponsor
- Azelon Pharmaceuticals
Leukemia
SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients
Granulocyte colony stimulating factor (G-CSF) is frequently used among patients with cancer including those with haematological malignancies.
- Trial name
- G-CSF (NCT01222819)
- Testing
- filgrastim
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Rabin Medical Center
Osteoporosis, Osteoporosis, Age-Related
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
- Conditions
- Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis
- Trial name
- NCT03512262
- Testing
- Abaloparatide
- Where
- 34 sites in United States, Italy and 1 more
- Volunteers
- 228 people
- Sponsor
- Radius Health, Inc.
Multiple Sclerosis
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
The purpose of this study is to test the RebiSmart™ for ease of use multiple domains related to subject's acceptability and satisfaction reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects…
- Trial name
- Performs (NCT01036165)
- Testing
- RebiSmart™
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- EMD Serono
Kaposi Sarcoma, HIV Infections
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept…
- Trial name
- NCT03157167
- Testing
- Tc99m-tilmanocept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Navidea Biopharmaceuticals
Arrhythmia, Cardiovascular Diseases
Evaluation of SC-V Versus Conventional CPR
To assess the benefits of a new method of cardiopulmonary resuscitation, SC-V CPR (simultaneous compression and ventilation CPR) in terms of short and long-term survival and lessened cerebral dysfunction.
- Conditions
- Arrhythmia, Cardiovascular Diseases, Heart Arrest, Heart Diseases
- Trial name
- NCT00000502
- Testing
- cardiopulmonary resuscitation
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)